非小细胞肺癌程序性死亡配体-1表达与临床病理特征和常见驱动基因变异的相关性研究

doi:10.11904/j.issn.1002-3070.2023.02.005

Abstract

Abstract: Objective The aim of this study was to analyze the correlation between the expression of programmed death ligand 1(PD-L1)and clinical pathological features and common driver gene mutation in patients with non-small cell lung cancer(NSCLC),so as to provide theoretical basis for immunotherapy of NSCLC patients. Methods Retrospective inclusion of NSCLC patients who underwent PD-L1 immunohistochemistry staining and epidermal growth factor receptor(EGFR),Kirsten rat sarcoma viral oncogene(KRAS),anaplastic lymphoma kinase(ALK),RET proto-oncogene(RET),v-Raf murine sarcoma viral oncogene homolog(BRAF),ROS proto-oncogene 1(ROS1),human epidermal growth factor receptor-2(HER2),cellular-mesenchymal to epithelial transition factor(MET)gene testing from the Pathology Department of Beijing Thoracic Hospital Affiliated to Capital Medical University from January 2018 to December 2021.Analysis of the impact of different pathological features and driver gene variants on PD-L1 protein expression in NSCLC patients. Results PD-L1 protein expression was detected in 2 386 cases,with a positive rate of 45.8%(1 093/2 386).Among them,the low expression group(1%≤TPS≤49%)was 62.0%(678/1 093),while the high expression group(TPS≥50%)was 38.0%(415/1 093).There were differences in PD-L1 expression among different clinical and pathological features.Multivariate logistic regression analysis showed that smoking history,lymph node metastasis,pathological subtypes,EGFR mutations,KRAS mutations,ALK and MET mutations were independent risk factors for PD-L1 expression in NSCLC patients(P＜0.05),while lymph node metastasis and EGFR mutations were independent risk factors for PD-L1 expression levels in NSCLC patients(P＜0.05). Conclusion The PD-L1 protein has a high positive rate in patients with smoking,squamous cell carcinoma,KRAS mutant,ALK positive,and MET mutant,and is highly expressed in patients with lymph node metastasis and EGFR wild-type.Different from NSCLC patients with EGFR positive,NSCLC patients with KRAS,and MET positive are expected to benefit from the treatment of immune checkpoint inhibitors.

Key words: Non-small cell lung cancer, Driver gene, Programmed death ligand-1, Immune checkpoint inhibitor

CLC Number:

R734

LONG Chaolian, LI Kun, LIU Zichen, ZHANG Nana, CHE Nanying. The correlation between the expression of programmed death ligand 1 in non-small cell lung cancer and clinical pathological features and common driver gene mutation[J]. Journal of Practical Oncology, 2023, 37(2): 117-122.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2023.02.005

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2023/V37/I2/117

References

1 Siegel RL,Miller KD,Fuchs HE,et al.Cancer Statistics,2021[J].CA Cancer J Clin,2021,71(1):7-33.
2 Zheng RS,Zhang SW,Zeng HM,et al.Cancer incidence and mortality in China,2016[J].JNCC,2022,2(1):1-9.
3 Herbst RS,Morgensztern D,Boshoff C.The biology and management of non-small cell lung cancer[J].Nature,2018,553(7689):446-454.
4 Bailey MH,Tokheim C,Porta-Pardo E,et al.Comprehensive characterization of cancer driver genes and mutations[J].Cell,2018,173(2):371-385.
5 Sánchez-Magraner L,Gumuzio J,Miles J,et al.Functional engagement of the PD-1/PD-L1 complex but not PD-L1 expression is highly predictive of patient response to immunotherapy in non-small-cell lung cancer.J Clin Oncol,2023,41(14):2561-2570.
6 Mok TSK,Wu YL,Kudaba I,et al.Pembrolizumab versus chemotherapy for previously untreated,PD-L1-expressing,locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042):a randomised,open-label,controlled,phase 3 trial[J].Lancet,2019,393(10183):1819-1830.
7 Teillaud JL,Dieu-Nosjean MC.Intratumoral plasma cells:More than a predictive marker of response to anti-PD-L1 treatment in lung cancer?[J].Cancer Cell,2022,40(3):240-243.
8 Miyazawa T,Marushima H,Saji H,Kojima K,et al.PD-L1 expression in non-small-cell lung cancer lncluding various adenocarcinoma subtypes[J].Ann Thorac Cardiovasc Surg,2019,25(1):1-9.
9 Gelatti ACZ,Cordeiro de Lima VC,Freitas H,et al.Real-world prevalence of PD-L1 expression among tumor samples from patients with non-small-cell lung cancer.Clin Lung Cancer,2020,21(6):e511-e515.
10 Pawelczyk K,Piotrowska A,Ciesielska U,et al.Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers.Int J Mol Sci,2019,20(4):824.
11 Dantoing E,Piton N,Salaün M,et al.Anti-PD1/PD-L1 immunotherapy for non-small cell lung cancer with actionable oncogenic driver mutations[J].Int J Mol Sci,2021,22(12):6288.
12 Hwang DM,Albaqer T,Santiago RC,et al.Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer[J].J Thorac Oncol,2021,16(9):1490-1500.
13 Peng DH,Rodriguez BL,Diao L,et al.Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers[J].Nat Commun,2021,10,12(1):2606.
14 Akbay EA,Koyama S,Carretero J,et al.Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors[J].Cancer Discov,2013,3(12):1355-1363.
15 Song Z,Yu X,Cheng G,et al.Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma[J].J Transl Med,2016,14(1):188.
16 Lee SE,Kim YJ,Sung M,et al.Association with PD-L1 expression and clinicopathological features in 1000 lung cancers:A large single-institution study of surgically resected lung cancers with a high prevalence of EGFR mutation[J].INT J MOL SCI,2019,20(19):4794.
17 Reck M,Carbone DP,Garassino M,et al.Targeting KRAS in non-small-cell lung cancer:recent progress and new approaches[J].Ann Oncol,2021,32(9):1101-1110.
18 Schoenfeld AJ,Rizvi H,Bandlamudi C,et al.Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas[J].Ann Oncol,2020,31(5):599-608.
19 Pan LN,Ma YF,Li Z,et al.KRAS G12V mutation upregulates PD-L1 expression via TGF-β/EMT signaling pathway in human non-small-cell lung cancer[J].Cell Biol Int,2021,45(4):795-803.
20 Yang CY,Liao WY,Ho CC,et al.Association of programmed death-ligand 1 expression with fusion variants and clinical outcomes in patients with anaplastic lymphoma kinase-positive lung adenocarcinoma receiving crizotinib[J].Oncologist,2020,25(8):702-711.
21 Ota K,Azuma K,Kawahara A,et al.Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer[J].Clin Cancer Res,2015,21(17):4014-4021.
22 Song Z,Yu X,Cheng G,et al.Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma[J].J Transl Med,2016,14(1):188.
23 Elangovan A,Allegretti JR,Fischer M.Microbiota modulation-based therapy for luminal GI disorders:current applications of probiotics and fecal microbiota transplantation.Expert Opin Biol Ther,2019,19(12):1343-1355.
24 王珊.PD-1/PD-L1蛋白表达与非小细胞肺癌K-RAS基因突变的相关性研究[D].唐山:华北理工大学,2017.
25 Kato S,Subbiah V,Marchlik E,et al.RET aberrations in diverse cancers:Next-generation sequencing of 4,871 patients[J].Clin Cancer Res,2017,23(8):1988-1997.
26 Mushtaq R,Cortot AB,Gautschi O,et al.PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case series[J].Transl Lung Cancer Res,2022,11(12):2412-2417.

[1]	YANG Lei, ZHANG Zhengfeng, WANG Dazhen, LOU Changjie. Real-world retrospective controlled study of first-line standard chemotherapy combined with immune checkpoint inhibitor versus standard chemotherapy for advanced esophageal squamous cell carcinoma [J]. Journal of Practical Oncology, 2022, 36(6): 538-543.
[2]	XU Zihan, YU Guohua, NIE Yuhui, SUN Mengmeng, FENG Hui, LIU Shuzhen. Predictive effect of peripheral blood markers on immune-related adverse reactions of advanced non-small cell lung cancer and their correlation with survival outcome [J]. Journal of Practical Oncology, 2022, 36(6): 544-550.
[3]	ZHU Kaibin, HE Changjun, CHEN Lantao, KONG Xianglong, ZHAO Su, XU Shidong. Tumor-associated macrophages promotes non-small cell lung cancer growth and tumor vascularization via PLGF/Flt-1 and TGF-β1 signal pathway [J]. Journal of Practical Oncology, 2022, 36(5): 391-397.
[4]	LIU Qianqian, SHANG Lihua. Research progress on the correlation between immune-related adverse reactions and efficacy of immunotherapy in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(5): 463-467.
[5]	DONG Lin, LIU Xin, LU Hailing. Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(4): 351-355.
[6]	ZHANG Hao, YANG Xinguan, HE Yong. Analysis of the correlation between sarcopenia and the clinicopathological characteristics and prognosis of advanced NSCLC [J]. Journal of Practical Oncology, 2022, 36(3): 214-219.
[7]	YI Xiaoqi, DENG Hongbin. Application progress of PD-1/PD-L1 inhibitors in neoadjuvant treatment of bladder cancer [J]. Journal of Practical Oncology, 2022, 36(2): 183-187.
[8]	TANG Ju, SHANG Lihua. The relationship between BMI and the efficacy of immune checkpoint inhibitors in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 188-192.
[9]	ZHANG Mengru, CAO Dedong, GE Wei. Comparison of efficacy and safety of Endostar intravenous continuous pumping and dripping combined with platinum-containing dual-drug regimen chemotherapy for the treatment of advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(1): 20-25.
[10]	LIU Jinshuang, ZHAGN Wenjing, LI Qingwei, LI Zhiwei. Research progress of therapies combined immune checkpoint inhibitors in pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(1): 49-53.
[11]	LUO Wen, JIA Li, ZHANG Jiawen, WANG Dongjie, KONG Yingjun. The effects of circRNA MYO1C on lung cancer cell autophagy and cancer stem cell differentiation [J]. Journal of Practical Oncology, 2021, 35(6): 500-505.
[12]	YU Yuanyuan, MENG Qianhao, WANG Guangyu. Dilemma and future direction of gastric cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 552-556.
[13]	LIU Fei, SUI Hong. Research progress in molecular classification of liver cancer based on tumor immunological microenvironment [J]. Journal of Practical Oncology, 2021, 35(6): 557-561.
[14]	LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 568-571.
[15]	WANG Ye, SHANG Naijian. Application progress of radiomics in the diagnosis and treatment of non-small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(5): 485-488.

The correlation between the expression of programmed death ligand 1 in non-small cell lung cancer and clinical pathological features and common driver gene mutation

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments